PARK2 mediates interleukin 6 and monocyte chemoattractant protein 1 production by human macrophages.
Leprosy is a persistent infectious disease caused by Mycobacterium leprae that still affects over 200,000 new patients annually. The host genetic background is an important risk factor for leprosy susceptibility and the PARK2 gene is a replicated leprosy susceptibility candidate gene. The protein product of PARK2, Parkin, is an E3 ubiquitin ligase that is involved in the development of various forms of Parkinsonism. The human macrophage is both a natural host cell of M. leprae as well as a primary mediator of natural immune defenses, in part by secreting important pro-inflammatory cytokines and chemokines. Here, we report that down-regulation of Parkin in THP-1 macrophages, human monocyte-derived macrophages and human Schwann cells resulted in a consistent and specific decrease in interleukin-6 (IL-6) and monocyte chemoattractant protein 1 (MCP-1/CCL2) production in response to mycobacteria or LPS. Interestingly, production of IL-6 at 6 hours by THP-1 cells stimulated with live M. leprae and M. bovis BCG was dependent on pretreatment with 1,25-dihydroxyvitamin D(3) (VD). Parkin knockdown in VD-treated cells blocked IL-6 induction by mycobacteria. However, IκB-α phosphorylation and levels of IκB-ξ, a nuclear protein required for IL-6 expression, were not affected by Parkin silencing. Phosphorylation of MAPK ERK1/2 and p38 was unaffected by Parkin silencing while JNK activation was promoted but did not explain the altered cytokine production. In a final set of experiments we found that genetic risk factors of leprosy located in the PARK2 promoter region were significantly correlated with M. leprae sonicate triggered CCL2 and IL6 transcript levels in whole blood assays. These results associated genetically controlled changes in the production of MCP-1/CCL2 and IL-6 with known leprosy susceptibility factors.
McGill Centre for the Study of Host Resistance, The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Louis
L
de Léséleuc
Marianna
M
Orlova
Aurelie
A
Cobat
Manon
M
Girard
Nguyen Thu
NT
Huong
Nguyen Ngoc
NN
Ba
Nguyen Van
NV
Thuc
Richard
R
Truman
John S
JS
Spencer
Linda
L
Adams
Vu Hong
VH
Thai
Alexandre
A
Alcais
Erwin
E
Schurr
D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000096:biosynthesis*; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D015850:Interleukin-6 / Q000096:biosynthesis*; D008070:Lipopolysaccharides / Q000276:immunology; D008264:Macrophages / Q000276:immunology*; D008297:Male; D009163:Mycobacterium bovis / Q000276:immunology; D009166:Mycobacterium leprae / Q000276:immunology; D012583:Schwann Cells / Q000276:immunology; D015398:Signal Transduction; D044767:Ubiquitin-Protein Ligases / Q000378:metabolism*
C111835:CCL2 protein, human; D018932:Chemokine CCL2; D015850:Interleukin-6; D008070:Lipopolysaccharides; D044767:Ubiquitin-Protein Ligases; C111567:parkin protein